# RAPA-501-Allo Therapy of COVID-19-ARDS

> **NCT04482699** · PHASE1,PHASE2 · TERMINATED · sponsor: **Rapa Therapeutics LLC** · enrollment: 1 (actual)

## Conditions studied

- Severe COVID-19 Disease

## Interventions

- **BIOLOGICAL:** RAPA-501-Allo off-the-shelf Therapy of COVID-19
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04482699
- **Lead sponsor:** Rapa Therapeutics LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-12-30
- **Primary completion:** 2021-09-13
- **Final completion:** 2021-09-13
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Change in eligible patient population
- **Last updated:** 2021-11-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04482699

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04482699, "RAPA-501-Allo Therapy of COVID-19-ARDS". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT04482699. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*